Debt-to-equity of AbCellera Biologics Inc. from 30 Sep 2021 to 31 Dec 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: AbCellera Biologics Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2021 to 31 Dec 2025.
AbCellera Biologics Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was 38%, a 32% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

AbCellera Biologics Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q4 2025	38%	+9.2%	+32%	31 Dec 2025
Q3 2025	35%	+6.1%	+21%	30 Sep 2025
Q2 2025	32%	+3.7%	+13%	30 Jun 2025
Q1 2025	29%	+0.33%	+1.1%	31 Mar 2025
Q4 2024	29%	+1.3%	+4.7%	31 Dec 2024
Q3 2024	29%	+2.4%	+9.2%	30 Sep 2024
Q2 2024	28%	+3%	+12%	30 Jun 2024
Q1 2024	29%	+2.7%	+10%	31 Mar 2024
Q4 2023	27%	-0.68%	-2.4%	31 Dec 2023
Q3 2023	26%	-2.6%	-9.1%	30 Sep 2023
Q2 2023	25%	-3.6%	-13%	30 Jun 2023
Q1 2023	26%	+0.08%	+0.3%	31 Mar 2023
Q4 2022	28%	+5.8%	+26%	31 Dec 2022
Q3 2022	29%	+8.8%	+43%	30 Sep 2022
Q2 2022	29%			30 Jun 2022
Q1 2022	26%			31 Mar 2022
Q4 2021	22%			31 Dec 2021
Q3 2021	20%			30 Sep 2021

* An asterisk sign (*) next to the value indicates that the value is likely invalid.